Why Speed Is No Longer Enough
In today’s pharmaceutical landscape, order of entry (OOE) is not destiny. Many brands still anchor their strategy to first-to-market thinking. Yet more than 50% of U.S. drug launches miss initial sales forecasts — not because of weak clinical data, but because strategies are designed for today’s signals rather than for the conditions that will exist at launch.
The core challenge is clear. Companies overweight clinical novelty and underweight access friction. They assume homogeneous customer behavior. Forecast models frequently over-index on efficacy while under-indexing on friction points such as prior authorization, affordability barriers, site-of-care setup, and prescriber or patient time burden. Brands arrive with compelling data but without sufficient proof of differentiated real-world value.
Therefore, building a go-to-market (GTM) model that meets real unmet needs at launch — where prescribers, patients, and payers assign value — is now non-negotiable.
Six Forces Reshaping Pharma GTM Strategy
1. Consumer-Grade Patient Expectations
Today’s patients demand more than clinical efficacy. They expect intuitive onboarding, transparent affordability, and digital self-service options that mirror their experiences in retail and banking. Proactive, personalized support is now a baseline expectation, not a differentiator. Consequently, winning brands design seamless journeys from e-prescribing to fulfillment, integrate real-time benefits verification, and prioritize human-in-the-loop support for both patients and providers.
2. Shift Toward Prevalent Disease Areas
The industry is swinging from niche specialty drugs toward large-scale therapies for chronic conditions — obesity, immunology, and mental health. U.S. prescription drug spending jumped 11.4% in 2024, adding roughly $50 billion to total pharmaceutical spend. GLP-1 agonists alone accounted for nearly 29% of that growth. Meanwhile, antidepressant prescriptions among adolescents climbed 63% after the pandemic. Mass-market products must, therefore, deliver seamless experiences across large, diverse populations and multiple channels simultaneously.
3. Escalating R&D Costs
Bringing a new drug to market costs approximately $2.6 billion and takes 10 to 15 years, with an FDA approval rate of only about 12%. As investment requirements increase, organizations must demonstrate clinical and economic impact from day one. Early, cross-functional planning between clinical, medical, and market access teams is essential to align evidence strategies with payer requirements.
4. Intensifying Competition Within and Beyond Class
Companies increasingly compete through care model integration and channel execution, not just clinical data. For instance, Pfizer’s collaboration with Sidekick Health delivered adherence improvements for 83% of users and a 40–50% reduction in symptom severity. Hybrid HCP engagement has also become a structural requirement. Success now hinges on shaping the ecosystem, educating on disease pathways, and executing with operational precision.
5. Evolving Policy and Payer Dynamics
Payers and governments are asserting stronger control over drug value. Access strategies must now incorporate fit-for-purpose evidence and outcomes-linked contracting. Moreover, pricing and market access strategies must synchronize with launch sequencing to avoid being disadvantaged under Inflation Reduction Act (IRA) and Most Favored Nation (MFN) pricing constraints. Selecting which indication to launch first is a strategic safeguard, not merely a commercial decision.
6. GenAI and Agentic AI Acceleration
With 48% of organizations planning to invest at least a quarter of their budgets in AI, the mandate is to scale with purpose. Pharma leaders are embedding GenAI into workflows for hyper-personalized engagement, dynamic targeting, and rapid feedback loops. Beyond customer-facing applications, AI is streamlining payer dossiers, sales training materials, and MLR reviews — achieving a 57% reduction in review cycle times. Additionally, AI involvement in clinical trials can reduce costs by up to 70% and timelines by 80%.
Case Studies: How Late Entrants Win
Tirzepatide vs. Semaglutide in Obesity
Despite semaglutide’s head start, tirzepatide leveraged targeted GTM tactics to capture and ultimately surpass its competitor’s market share. Tirzepatide’s manufacturer priced its product at approximately $1,080 per month — below semaglutide’s $1,300 entry point — while introducing single-dose formats and building a direct-to-patient telehealth ecosystem. Partnerships with telehealth providers and major retail pharmacies expanded access to 4,600 in-store locations, setting a new convenience benchmark for obesity medicine.
Faricimab in Ophthalmology
Faricimab replaced ranibizumab and captured significant share from aflibercept in wet AMD treatment. It differentiated through extended dosing intervals, prefilled syringes, and one-hand administration — features that directly addressed patient and clinic burden. Furthermore, targeted DTC campaigns highlighting lifestyle benefits (“fewer clinic visits, same results”) built patient demand in a category previously driven solely by specialist relationships.
Key Drivers of GTM Success
Market Shaping: Start Early
Decision criteria harden quickly. Research shows that roughly 80% of new drug launches fail to materially improve their initial sales trajectory within the first six months to two years. Companies that underinvest early in market shaping rarely recover. To win, brands must define valued attributes, enable the ecosystem, and set economic expectations — regardless of whether they are first, second, or third to market.
Segmentation: Know Where to Play
Commercial success begins with thoughtful segmentation. Understanding what customers truly want — clinical outcomes, convenience, affordability, or support — shapes both product and service design. Early positioning is critical. Brands must define their unique value proposition and target segments well before launch to achieve meaningful differentiation.
Market Access: A Strategic Priority, Not a Hurdle
Securing market access must begin at product development, not at approval. Early payer engagement, outcomes-linked contracting, and pre-launch education reduce friction at launch. Companies that integrate access planning upstream accelerate uptake and reduce coverage delays significantly.
Supply Chain Readiness
Supply chain resilience is now a competitive differentiator. High-profile delays — such as aflibercept HD formulation setbacks tied to fill-finish manufacturing — illustrate how strong clinical assets can still face headwinds. In contrast, therapies with flexible manufacturing footprints can capture market opportunities immediately rather than rationing supply.
Common Launch Pitfalls to Avoid
Even promising strategies can be derailed. Launch teams should actively watch for these missteps:
- Under-investing in evidence generation and patient experience design
- Targeting the average customer rather than high-need micro-segments
- Shaping the market too late, after decision criteria have already hardened
- Generating data that payers and real-world decision-makers do not value
- Scaling too quickly, putting service quality and price integrity at risk
Conclusion: Build for the Market That Will Exist
The pharmaceutical launch environment is no longer defined by speed or novelty alone. Instead, success depends on anticipating what prescribers, patients, and payers will value at the moment of launch — and building strategies accordingly. Organizations must invest early in market shaping, design consumer-grade experiences that reduce friction, and align evidence generation with real-world payer needs.
